Biofrontera AG

B8FK

DE000A4BGGM7

Pharmaceuticals

End-of-day quote Xetra Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
3.51 ^EUR	-1.40%		-48.41%	-58.32%

May. 15	Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M	MT
Apr. 30	Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Biofrontera AG Provides Revenue Guidance for the Financial Year 2020

July 14, 2020 at 06:08 am EDT

Biofrontera AG provided revenue guidance for the financial year 2020. For the year, the company confirms its budget assumption for sales revenue for the 2020 financial year of EUR 34 million to EUR 38 million.

Latest news about Biofrontera AG

Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M	May. 15	MT
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	Mar. 11	MT
Medicus Pharma Names COO	Mar. 05	MT
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	Nov. 09	MT
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	23-10-10	MT
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	23-10-03	DJ
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	23-08-28	MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M	23-08-11	MT
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	23-08-10	MT
Top Premarket Decliners	23-07-21	MT
Biofrontera Launches Novel Belixos Active Care	23-07-05	CI
Biofrontera to Effect 1-for-20 Reverse Stock Split	23-07-03	MT
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected	23-06-20	MT
Transcript : Biofrontera AG, Q1 2023 Earnings Call, May 31, 2023	23-05-31
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial	23-05-17	CI
Biofrontera Says it Obtained US Patent for New Photodynamic Therapy Protocol	23-05-15	MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $8.7M, vs. Street Est of $9.2M	23-05-12	MT
Biofrontera Enters $6.5 Million Line of Credit With MidCap Business Credit	23-05-11	MT
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Biofrontera Reports Completion of Last Patient Visit in Phase 1 Study to Treat Actinic Keratosis	23-04-26	MT
Biofrontera to Grow Salesforce 'Meaningfully' in 2023	23-03-27	MT

Chart Biofrontera AG

Duration

Period

More charts

Company Profile

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Sector

Pharmaceuticals

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOFRONTERA AG	-58.32%	11.45M
ELI LILLY AND COMPANY	+34.35%	705B
NOVO NORDISK A/S	+31.13%	583B
JOHNSON & JOHNSON	-3.49%	364B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	291B
ASTRAZENECA PLC	+15.17%	238B
ROCHE HOLDING AG	-3.56%	210B
NOVARTIS AG	+10.12%	209B
AMGEN INC.	+9.21%	169B

Other Pharmaceuticals

Biofrontera AG

Equities

B8FK

DE000A4BGGM7

Pharmaceuticals

Biofrontera AG Provides Revenue Guidance for the Financial Year 2020

Latest news about Biofrontera AG

Chart Biofrontera AG

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals